Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL
Jiang E, Yu M, Hsieh Y, DeLaTorre B, Kadavallore A, Scharman C, Park E, Yang A, Muschen M, Groffen J, Heisterkamp N, Kim Y. Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL. Blood 2008, 112: 2922. DOI: 10.1182/blood.v112.11.2922.2922.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaNOD/SCIDDrug-resistant leukemia cellsResistant leukemia cellsLeukemia cellsPreclinical evaluationPre-clinical xenograft modelNOD/SCID miceAcute lymphoblastic leukemia cellsCombination of AMD3100Different chemotherapeutic regimensNew treatment modalitiesLong-term survivalPrimary lymphoid organsLymphoblastic leukemia cellsTail vein injectionFurther preclinical evaluationCXCL12-CXCR4 interactionProgression of leukemiaB cell precursorsHigh death rateInteraction of CXCL12Clear beneficial effectPhiladelphia Chromosome PositiveBone marrow fibroblastsBCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia
Duy C, Yu J, Cerchietti L, Klemm L, Nahar R, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jumaa H, Melnick A, Ye B, Muschen M. BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. Blood 2008, 112: 295. DOI: 10.1182/blood.v112.11.295.295.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaGerminal center B cellsImatinib treatmentBCR-ABL1Bone marrowB cellsLymphoblastic leukemiaHuman BCR-ABL1NOD/SCID miceFunction of Bcl6Inhibition of BCL6Low-dose imatinibBCL6 expressionLeukemia cellsP53 signalingProtein levelsCombination of imatinibGerminal center B cell survivalTail vein injectionNovel treatment conceptsTranscriptional repressor BCL6B cell survivalLow proliferation rateRecipient miceSCID mice